prodchem
Aug 28, 2026
Clariant’s appointment of Oliver Rittgen as chief financial officer has brought a finance leader with direct agricultural-chemicals experience into the company’s top management at a time when its Crop Solutions business is being evaluated alongside broader portfolio, cost and capital-allocation priorities.
Rittgen became Clariant’s CFO on August 1, 2025, succeeding Bill Collins. Before joining Clariant, he spent 25 years in senior roles at Bayer, including serving as CFO of Bayer’s Crop Science division from February 2024 to July 2025.
That background gives Clariant a finance chief who has already worked inside one of the world's largest agricultural-chemicals businesses.
The timing is significant because Clariant's Crop Solutions portfolio is part of its Care Chemicals business, where management is simultaneously pursuing portfolio pruning, cost improvements and higher-value growth.
The most distinctive element of Clariant's new finance leadership is Rittgen's previous role at Bayer.
As CFO of Bayer Crop Science, he was exposed to the financial and strategic dynamics of a global agricultural business spanning crop-protection products, seeds and related technologies.
That experience differs from a conventional industrial CFO background.
Agricultural chemicals require financial decisions around highly seasonal demand, regulatory cycles, product registrations, formulation economics, inventory levels and relationships with major agrochemical manufacturers.
Rittgen therefore arrives at Clariant with experience relevant to the economics of one of its more specialized businesses.
Clariant does not operate Crop Solutions as a standalone business unit.
It is part of Care Chemicals, alongside businesses including Personal & Home Care, Industrial Applications, Base Chemicals, Oil Services and Mining Solutions.
This structure means agricultural chemicals compete for capital and management attention with a much broader set of specialty-chemical applications.
The finance function consequently has an important role in determining where investment should be directed.
A project serving Crop Solutions must compete not only against other agricultural opportunities but also against investments in personal care, industrial applications, mining and other specialty-chemical markets.
Clariant's Crop Solutions business experienced a difficult year-over-year comparison in 2026.
In the first quarter, the company said Crop Solutions sales declined against a strong prior-year comparison that had benefited from restocking.
The same dynamic continued into the second quarter.
Clariant reported that Crop Solutions sales declined because of lower volumes against a high comparison base created by the previous year's restocking cycle.
That does not necessarily indicate structural weakness.
Management said it expected growth to return during the second half of 2026, supported particularly by the branded agricultural-chemical customers that make up the majority of Clariant's Crop Solutions customer base.
For a CFO, distinguishing between temporary inventory normalization and genuine portfolio deterioration is critical.
One important characteristic of Crop Solutions is its customer mix.
During Clariant's July 2026 earnings discussion, Rittgen said the majority of Crop Solutions customers are in branded businesses, meaning the segment is less exposed to the generic-agrochemical market.
That distinction matters because generic crop-protection products can experience intense price competition and rapid changes in supply dynamics.
A portfolio serving branded agricultural companies can potentially offer greater emphasis on formulation performance, differentiated additives and technical value.
This aligns with Clariant's broader strategy of focusing on specialty applications rather than competing purely on commodity pricing.
Clariant entered 2026 with an explicit emphasis on cost control and capital efficiency.
During the first half, the company generated CHF 168.7 million in operating cash flow, compared with CHF 115.9 million in the prior-year period.
It also maintained disciplined capital expenditure and improved free-cash-flow conversion to 52% on a last-twelve-month basis.
At the same time, Clariant expanded its performance-improvement program to a CHF 100 million annual run rate by 2027, with CHF 90 million expected in 2026.
That environment makes the CFO's role particularly important.
New investment will increasingly need to demonstrate not only strategic relevance but also clear returns, cash-flow potential and resilience through the chemical cycle.
Clariant has already been actively reshaping its portfolio.
The company said its 2026 sales were affected by portfolio-pruning measures, including within Care Chemicals.
This means the question facing management is not simply whether to invest more.
It is also where not to invest.
For Crop Solutions, that could mean concentrating resources on products and technologies where Clariant has differentiated chemistry, strong customer relationships or defensible margins.
The company is unlikely to benefit from simply expanding agricultural exposure for its own sake.
Crop-protection manufacturers increasingly require specialty ingredients and formulation technologies that improve the performance, stability and application of active ingredients.
This creates an opportunity for companies such as Clariant.
Instead of competing directly with large crop-protection companies on active ingredients, Clariant can provide specialty chemicals that support agricultural formulations.
Its position is therefore closer to an enabling supplier within the agricultural-chemicals value chain.
That can make innovation and customer-specific technical support more important than simply increasing production volumes.
Rittgen's Bayer Crop Science experience could influence how Clariant evaluates these opportunities.
A finance leader with direct agricultural exposure is familiar with questions such as:
How much of demand reflects true end-market consumption?
How much is inventory restocking or destocking?
Which customers have stronger pricing power?
Which products face generic competition?
How should regulatory risk affect investment decisions?
Which innovation projects can support sustainable margins?
How much working capital is required across seasonal demand cycles?
These considerations are particularly relevant when agricultural-chemical markets experience large swings between stocking and destocking.
Clariant's strategy could therefore favor selective investment rather than broad expansion.
Projects most likely to receive support would be those that:
Address a clear formulation or performance challenge.
Have strong relationships with branded agrochemical customers.
Provide differentiated functionality.
Offer attractive margins relative to capital requirements.
Can generate recurring demand.
Fit Clariant's existing manufacturing and technology infrastructure.
This approach would be consistent with the company's broader emphasis on value-based pricing and differentiated solutions.
The financial context also makes Care Chemicals strategically important.
In the second quarter of 2026, Care Chemicals generated CHF 503.7 million in sales, while EBITDA before exceptional items reached CHF 104.2 million, producing a 20.7% margin.
The business benefited from strong performance in areas such as Personal & Home Care, Industrial Applications and Mining Solutions.
Crop Solutions was weaker because of the comparison with the prior year's restocking-driven growth.
This contrast demonstrates the portfolio-management challenge.
Clariant must determine where its strongest returns are being generated and where additional investment can improve the overall quality of the Care Chemicals portfolio.
Rittgen's appointment should therefore not be interpreted as evidence that Clariant is preparing for a major expansion in agriculture.
The company's leadership structure remains organized around three major business areas:
Care Chemicals & Americas
Catalysts & APAC
Adsorbents & Additives & EMEA
The CFO sits alongside these business presidents on Clariant's Executive Steering Committee, which has overall strategic and financial responsibility for the company.
Agriculture is consequently one component of a much broader portfolio.
Rittgen's value may lie precisely in his ability to compare agricultural opportunities against competing uses of capital across Clariant.
The new finance leadership could also strengthen the connection between operational data and investment decisions.
Agricultural-chemical demand can be difficult to interpret because sales can move sharply depending on distributor inventories, crop cycles, weather conditions and regional planting patterns.
A CFO with direct Crop Science experience may be particularly sensitive to separating reported sales growth from underlying demand.
That distinction is important for determining whether Clariant should increase production, build inventory, invest in capacity or instead wait for normalization.
Management's expectations for Crop Solutions make the second half of 2026 particularly relevant.
Clariant expects growth to return as the comparison with the previous year's restocking period becomes less demanding and branded agricultural customers support volume recovery.
If that recovery occurs, it would strengthen the argument for continued targeted investment in the segment.
If demand remains weak despite normalization of the comparison base, management may have greater incentive to accelerate portfolio pruning or redirect capital toward higher-return businesses.
Either outcome would provide useful information for the company's longer-term capital-allocation strategy.
In a specialty-chemical company, finance leadership can have an outsized influence on portfolio development.
A business may have strong technical potential but still fail to justify investment if it requires excessive working capital, has weak pricing power or faces uncertain returns.
Conversely, a relatively small product line can become strategically important if it delivers high margins, recurring demand and strong customer retention.
That makes financial evaluation especially important for Clariant's agricultural-chemical activities.
Rittgen's previous experience in Crop Science could provide an additional layer of sector-specific judgment when these trade-offs are made.
Clariant's appointment of Oliver Rittgen as CFO gives the company a finance leader with unusually direct experience in agricultural chemicals.
His previous position as CFO of Bayer's Crop Science division means he enters Clariant with an understanding of the financial dynamics of global agriculture, including the importance of inventory cycles, branded customers, portfolio management and capital allocation.
The timing is significant.
Clariant is simultaneously pursuing cost savings, portfolio pruning and disciplined capital deployment while seeking growth across its specialty-chemicals businesses. Its Crop Solutions segment has faced a difficult year-over-year comparison in 2026 but management expects growth to return in the second half.
Rittgen's influence is therefore unlikely to mean that Clariant will simply spend more on agricultural chemicals.
The more likely impact is greater selectivity over where capital goes.
For Crop Solutions, that could favor differentiated formulation technologies, branded agrochemical customers and products capable of sustaining specialty-chemical margins.
In that sense, Clariant's new finance leadership could become important not because it changes the company's agricultural strategy overnight, but because it may determine which parts of that strategy receive the investment required to grow.
Featured Product
Found this useful?
Continue Reading
IG4 Capital's broader industrial investment pattern, now including its pending Braskem stake
Schrödinger's computational chemistry technology helped shape Ajax Therapeutics from its 2019 founding, and Lilly's acquisition now brings that platform and its JAK2 program deeper into a major pharmaceutical pipeline.
Brazilian agrochemical producers dependent on Braskem-supplied petrochemical intermediates are watching the IG4
